Activation of the Integrated Stress Response in drug-tolerant melanoma cells confers vulnerability to mitoribosome-targeting antibiotics

Therapy resistance remains a major clinical challenge for the management of metastatic melanoma. Here we show that activation of the Integrated Stress Response (ISR), which we show is common in drug-tolerant and resistant melanoma, promotes selective synthesis of mitochondrial proteins in the cytosol. Since mitochondrial translation adapts to the influx of nuclear-encoded mitochondrial proteins, ISR activation indirectly enhances mitochondrial translation and makes these cells highly vulnerable to mitochondrial translation inhibitors. Treatment of melanoma with mitoribosome-targeting antibiotics, induces proteotoxic stress and significantly compromises the growth of NRAS-mutant and immunotherapy-resistant skin melanoma as well as uveal melanoma. Additionally, a triple BRAFi/MEKi/Tigecycline combination reduces intratumour heterogeneity by abrogating emergence of dedifferentiated drug-tolerant cells, and delayed or even prevented the development of resistance in BRAFV600E PDX models. Consistently, a melanoma patient exposed to Doxycycline, a mitoribosome-targeting antibiotic commonly used to treat infections, experienced a complete and long-lasting response of a treatment-resistant lesion. Significance Our study indicates that the repurposing of mitoribosome-targeting antibiotics offers a rational salvage strategy for targeted therapy in BRAF-mutant melanoma, and a therapeutic option to target NRAS-driven and immunotherapy-resistant cutaneous melanoma and uveal melanomas.

[1]  J. Wilmott,et al.  Transcriptional downregulation of MHC class I and melanoma de- differentiation in resistance to PD-1 inhibition , 2020, Nature Communications.

[2]  M. Briggs.  Faculty Opinions recommendation of Endoplasmic reticulum stress signalling - from basic mechanisms to clinical applications. , 2020 .

[3]  B. Faubert,et al.  Metabolic reprogramming and cancer progression , 2020, Science.

[4]  H. Zischka,et al.  A pathway coordinated by DELE1 relays mitochondrial stress to the cytosol , 2020, Nature.

[5]  E. Mjolsness,et al.  Transcriptional diversity and bioenergetic shift in human breast cancer metastasis revealed by single-cell RNA sequencing , 2020, Nature Cell Biology.

[6]  Gary D Bader,et al.  Relapse fated latent diagnosis subclones in acute B lineage leukaemia are drug tolerant and possess distinct metabolic programs. , 2020, Cancer discovery.

[7]  Ke Xu,et al.  Mitochondrial stress is relayed to the cytosol by an OMA1-DELE1-HRI pathway , 2020, Nature.

[8]  Evan G. Williams,et al.  A Conserved Mito-Cytosolic Translational Balance Links Two Longevity Pathways. , 2020, Cell metabolism.

[9]  P. Carmeliet,et al.  PHD1 controls muscle mTORC1 in a hydroxylation-independent manner by stabilizing leucyl tRNA synthetase , 2020, Nature Communications.

[10]  T. Ketela,et al.  Inhibition of mitochondrial translation overcomes venetoclax resistance in AML through activation of the integrated stress response , 2019, Science Translational Medicine.

[11]  F. D. de Sauvage,et al.  The great escape: tumour cell plasticity in resistance to targeted therapy , 2019, Nature Reviews Drug Discovery.

[12]  J. Marine,et al.  Melanoma plasticity and phenotypic diversity: therapeutic barriers and opportunities , 2019, Genes & development.

[13]  Guoan Chen,et al.  Targeting lonidamine to mitochondria mitigates lung tumorigenesis and brain metastasis , 2019, Nature Communications.

[14]  P. A. Futreal,et al.  Molecular Profiling Reveals Unique Immune and Metabolic Features of Melanoma Brain Metastases. , 2019, Cancer discovery.

[15]  F. Azuaje,et al.  Inhibition of mitochondrial respiration prevents BRAF-mutant melanoma brain metastasis , 2019, Acta neuropathologica communications.

[16]  I. Dutta,et al.  Translational control of breast cancer plasticity , 2019, bioRxiv.

[17]  P. Jagust,et al.  Metabolism-Based Therapeutic Strategies Targeting Cancer Stem Cells , 2019, Front. Pharmacol..

[18]  D. Ding,et al.  SMARCAD1 ATPase activity is required to silence endogenous retroviruses in embryonic stem cells , 2019, Nature Communications.

[19]  P. Nghiem,et al.  Faculty Opinions recommendation of A cancer cell program promotes T cell exclusion and resistance to checkpoint blockade. , 2019, Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature.

[20]  G. Cook,et al.  Genetic and Environmental Determinants of Immune Response to Cutaneous Melanoma. , 2019, Cancer research.

[21]  J. McQuade,et al.  Modulating the microbiome to improve therapeutic response in cancer. , 2019, The Lancet. Oncology.

[22]  Lucas Goedert,et al.  Control of nucleolar stress and translational reprogramming by lncRNAs , 2018, Cell stress.

[23]  P. Sanseau,et al.  Drug repurposing: progress, challenges and recommendations , 2018, Nature Reviews Drug Discovery.

[24]  K. Flaherty,et al.  Toward Minimal Residual Disease-Directed Therapy in Melanoma , 2018, Cell.

[25]  P. Agostinis,et al.  Endoplasmic reticulum stress signalling – from basic mechanisms to clinical applications , 2018, The FEBS journal.

[26]  B. Comin-Anduix,et al.  Immunotherapy Resistance by Inflammation-Induced Dedifferentiation. , 2018, Cancer discovery.

[27]  T. Graeber,et al.  Multi-stage Differentiation Defines Melanoma Subtypes with Differential Vulnerability to Drug-Induced Iron-Dependent Oxidative Stress. , 2018, Cancer cell.

[28]  F. DiMeco,et al.  Constitutive and TNFα-inducible expression of chondroitin sulfate proteoglycan 4 in glioblastoma and neurospheres: Implications for CAR-T cell therapy , 2018, Science Translational Medicine.

[29]  M. Giorgio,et al.  Therapeutic synergy between tigecycline and venetoclax in a preclinical model of MYC/BCL2 double-hit B cell lymphoma , 2018, Science Translational Medicine.

[30]  P. Parren,et al.  Cooperative targeting of melanoma heterogeneity with an AXL antibody-drug conjugate and BRAF/MEK inhibitors , 2018, Nature Medicine.

[31]  Riyue Bao,et al.  The commensal microbiome is associated with anti–PD-1 efficacy in metastatic melanoma patients , 2018, Science.

[32]  T. Graeber,et al.  Single-cell analysis resolves the cell state transition and signaling dynamics associated with melanoma drug-induced resistance , 2017, Proceedings of the National Academy of Sciences.

[33]  Robert W. Williams,et al.  Multi-omics analysis identifies ATF4 as a key regulator of the mitochondrial stress response in mammals , 2017, The Journal of cell biology.

[34]  K. Blenman,et al.  UV‐induced somatic mutations elicit a functional T cell response in the YUMMER1.7 mouse melanoma model , 2017, Pigment cell & melanoma research.

[35]  Cole M. Haynes,et al.  Mitochondrial dysfunction in cancer: Potential roles of ATF5 and the mitochondrial UPR. , 2017, Seminars in cancer biology.

[36]  Liang Xu,et al.  Doxycycline inhibits the cancer stem cell phenotype and epithelial-to-mesenchymal transition in breast cancer , 2017, Cell cycle.

[37]  D. McConkey.  The integrated stress response and proteotoxicity in cancer therapy. , 2017, Biochemical and biophysical research communications.

[38]  In This Issue , 2017, Proceedings of the National Academy of Sciences of the United States of America.

[39]  Matthew J. Daniels,et al.  Translation reprogramming is an evolutionarily conserved driver of phenotypic plasticity and therapeutic resistance in melanoma , 2017, Genes & development.

[40]  A. Shamas-Din,et al.  A Phase 1 study of intravenous infusions of tigecycline in patients with acute myeloid leukemia , 2016, Cancer medicine.

[41]  S. Oeljeklaus,et al.  Mitochondrial Protein Synthesis Adapts to Influx of Nuclear-Encoded Protein , 2016, Cell.

[42]  M. Bosenberg,et al.  The YUMM lines: a series of congenic mouse melanoma cell lines with defined genetic alterations , 2016, Pigment cell & melanoma research.

[43]  M. Giorgio,et al.  The mitochondrial translation machinery as a therapeutic target in Myc-driven lymphomas , 2016, Oncotarget.

[44]  C. Horak,et al.  Efficacy and Safety of Nivolumab in Patients With BRAF V600 Mutant and BRAF Wild-Type Advanced Melanoma: A Pooled Analysis of 4 Clinical Trials. , 2015, JAMA oncology.

[45]  R. M. Owen,et al.  An analysis of the attrition of drug candidates from four major pharmaceutical companies , 2015, Nature Reviews Drug Discovery.

[46]  Evan G. Williams,et al.  Tetracyclines Disturb Mitochondrial Function across Eukaryotic Models: A Call for Caution in Biomedical Research. , 2015, Cell reports.

[47]  H P Soyer,et al.  A stress-induced early innate response causes multidrug tolerance in melanoma , 2014, Oncogene.

[48]  L. Richards-Peterson,et al.  The Metabolic Drug-Drug Interaction Profile of Dabrafenib: In Vitro Investigations and Quantitative Extrapolation of the P450-Mediated DDI Risk , 2014, Drug Metabolism and Disposition.

[49]  P. Johnston,et al.  Cancer drug resistance: an evolving paradigm , 2013, Nature Reviews Cancer.

[50]  J. Collins,et al.  Bactericidal Antibiotics Induce Mitochondrial Dysfunction and Oxidative Damage in Mammalian Cells , 2013, Science Translational Medicine.

[51]  P. Gimotty,et al.  Overcoming intrinsic multidrug resistance in melanoma by blocking the mitochondrial respiratory chain of slow-cycling JARID1B(high) cells. , 2013, Cancer cell.

[52]  T. Graeber,et al.  Doxycycline Alters Metabolism and Proliferation of Human Cell Lines , 2013, PloS one.

[53]  Jun S. Song,et al.  Oncogenic BRAF regulates oxidative metabolism via PGC1α and MITF. , 2013, Cancer cell.

[54]  J. Landsberg,et al.  Melanomas resist T-cell therapy through inflammation-induced reversible dedifferentiation , 2012, Nature.

[55]  E. Chen.  Mitochondrial dysfunction and cancer metastasis , 2012, Journal of Bioenergetics and Biomembranes.

[56]  Yu Shyr,et al.  Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. , 2012, The New England journal of medicine.

[57]  G. Giaever,et al.  Inhibition of mitochondrial translation as a therapeutic strategy for human acute myeloid leukemia. , 2011, Cancer cell.

[58]  A. Magill,et al.  Doxycycline for Malaria Chemoprophylaxis and Treatment: Report from the CDC Expert Meeting on Malaria Chemoprophylaxis , 2011, The American journal of tropical medicine and hygiene.

[59]  F. Sörgel,et al.  Penetration of Drugs through the Blood-Cerebrospinal Fluid/Blood-Brain Barrier for Treatment of Central Nervous System Infections , 2010, Clinical Microbiology Reviews.

[60]  Ben S. Wittner,et al.  A Chromatin-Mediated Reversible Drug-Tolerant State in Cancer Cell Subpopulations , 2010, Cell.

[61]  A. Harris,et al.  Role of ATF4 in regulation of autophagy and resistance to drugs and hypoxia , 2009, Cell cycle.

[62]  Philippe Pierre,et al.  SUnSET, a nonradioactive method to monitor protein synthesis , 2009, Nature Methods.

[63]  A. Trumpp,et al.  Mechanisms of Disease: cancer stem cells—targeting the evil twin , 2008, Nature Clinical Practice Oncology.

[64]  M. Hung,et al.  Breast cancer brain metastases , 2007, Cancer and Metastasis Reviews.

[65]  J. Yates,et al.  Adaptation of energy metabolism in breast cancer brain metastases. , 2007, Cancer research.

[66]  C. Onyeji,et al.  Effects of tetracycline on the pharmacokinetics of halofantrine in healthy volunteers. , 2004, British journal of clinical pharmacology.

[67]  S. Weinberg,et al.  Targeting mitochondria metabolism for cancer therapy. , 2015, Nature chemical biology.